Skip to content Skip to footer
Subscribe Now

NEWS

Rznomics and Eli Lilly
Rznomics Partners with Eli Lilly for RNA Editing Therapeutics
Shots: Rznomics has signed a strategic global license agreement with Eli Lillyto develop & commercialize RNA-editing therapies for inherited hearing loss using Rznomics' trans-splicing ribozyme platform As per the deal, if Lilly avail all its options then total deal value could surpass $1.3B with undisclosed upfront payment, in addition to separate royalties from product sales The…
May 16, 2025
Abbvie
AbbVie’s Emrelis Receives the US FDA’s Accelerated Approval for NSCLC With High c-Met Protein Overexpression
Shots: The US FDA has granted accelerated approval to Emrelis (telisotuzumab vedotin-tllv) for treatment-experienced pts with locally advanced or metastatic, c-Met overexpressing, non-squamous NSCLC  Approval was backed by an ongoing P-II (LUMINOSITY) study assessing Emrelis as 2L/3L treatment of c-Met overexpressing NSCLC; showing an ORR of 35% & mDoR of 7.2mos. in pts (n=84) with…
May 16, 2025
Pet Pace
TelmyVet and PetPace Launch Quality-of-Life Consultation to Support Pets and Families in End-of-Life Care
Shots: TelmyVet & PetPace have launched the Quality-of-Life Consultation, a virtual care service to support pets & their families during end-of-life stages Service combines TelmyVet’s telemedicine platform with PetPace’s AI-powered smart collar, which tracks HRV, vital signs, mobility, & behavior to assess pain & stress. It offers a supportive space for pet parent guidance &…
May 15, 2025
AbbVie & ADARx Pharmaceuticals
AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas
Shots: AbbVie has entered into collaboration & license option agreement with ADARx to develop siRNA therapeutics across multiple disease areas, incl. neuroscience, immunology & oncology, leveraging ADARx's RNA tech As per the deal, ADARx will receive $335M upfront & will be eligible to receive several billion in additional contingent payments incl. option fees, milestones, plus tiered royalties…
May 15, 2025
Genesys Spine
Genesys Spine Unveils Stasys-C 3DP Cervical Standalone System to Streamline Anterior Cervical Procedures
Shots: Genesys Spine has launched its Stasys-C 3DP Cervical Standalone System to simplify anterior cervical procedures Stasys-C has a non-screw-based fixation method with quick, non-impacting anchor deployment via a direct anterior approach, plus it has Quick Turn Cam Lock, which allows visual anchor engagement & locking confirmation, while the SemaFour surface design maximizes wettability, surface…
May 15, 2025
Novo Nordisk and Septerna
Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
Shots: Septerna & Novo Nordisk to identify, develop & market oral small molecules for obesity, T2D & other cardiometabolic diseases under an exclusive global collaboration & license agreement As per the deal, Septerna will receive ~$2.2B, incl. over $200M in upfront & near-term milestones, plus research, development, & commercial milestones, along with net sales-based tiered…
May 15, 2025
Load more